ClinicalTrials.gov
public full text
Public Domain
Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease
The primary objective of this study is to demonstrate that transdermal nicotine treatment retards disease progression as measured by change in total Unified Parkinson's Disease Rating Scale (UPDRS)(part I, II, III)score between baseline and after 52 weeks of study treatment plus two more months wash out (60 weeks).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- High Frequency and Intensive Prevention Program#1073549
- tDCS for Dual-task Performance in Patients With PD#966871
- ROADSTER 3 Extended Follow-up Sub-Study#860850
- Impact of Virtual Reality-Based Therapies on Cognition and Depression in Patients With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.#330907
- The Role of DLOTCA-G in the Cognitive Function Evaluation of Parkinson's Patients#914307
Record · ID 857271
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive